miebo: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675	NDA	Bausch & Lomb Incorporated	24208-377-01	1 BOTTLE in 1 CARTON (24208-377-01) / 3 mg in 1 BOTTLE	2023-05-18
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675	NDA	Bausch & Lomb Incorporated	24208-377-05	1 BOTTLE in 1 CARTON (24208-377-05) / 3 mg in 1 BOTTLE	2023-05-18
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 27, 2025

Introduction

MIEBO, a pharmaceutical compound marketed primarily as a synthetic cannabinoid receptor agonist, has garnered attention in various contexts, including medical research, therapeutics, and, occasionally, illicit use. Its unique pharmacological profile has led to a burgeoning demand across diverse channels, prompting exploration into its supply chain. This article provides a comprehensive analysis of suppliers involved in the production and distribution of MIEBO, examining manufacturing sources, regulatory landscapes, and key market players. Understanding these supply dynamics is essential for stakeholders assessing compliance, procurement strategies, and market entry considerations.

Understanding MIEBO: Chemical Profile and Market Context

MIEBO, chemically known as N-(1-(4-methoxyphenyl)-2-(1-methyl-1H-indol-3-yl)ethyl)acetamide, belongs to the indole and phenylamine classes, with notable activity on cannabinoid receptors. Its synthetic nature renders it a lab-created compound, with production predominantly centralized within specialized chemical manufacturing facilities. Although initially developed for research purposes, its pharmacological activity has seen it exploited in niche markets, including illicit recreational drug trade and experimental therapeutics.

Primary Manufacturers and Raw Material Suppliers

1. Contract Chemical Manufacturers

Most commercial suppliers do not produce MIEBO as a standard product but instead offer custom synthesis services tailored to client specifications. These contract manufacturers possess advanced chemical synthesis capabilities, often located in regions with robust pharmaceutical manufacturing infrastructure, such as China, India, and certain European countries.

China: Dominates in high-volume chemical synthesis, with numerous contract labs providing custom cannabinoid receptor agonists, including MIEBO. Companies such as ABA Laboratories and Shenzhen ChemPharm have established protocols for synthesizing complex indole derivatives.
India: Several firms, including Neuland Laboratories and Biocon, offer research-grade synthesis services. These facilities often supply intermediates used in MIEBO production, such as substituted indoles and phenyl derivatives.
Europe: Notable for stringent regulatory standards, European manufacturers like Evonik Industries and Siegfried AG provide high-purity active pharmaceutical ingredients (APIs), primarily for registered medicinal applications. Their involvement in MIEBO is limited but relevant in the context of compliant supply chains.

2. Raw Material Suppliers

The synthesis of MIEBO requires key intermediates, including:

Methoxyphenyl compounds: Suppliers provide anisole derivatives, often sourced globally from chemical intermediates manufacturers like Sigma-Aldrich (now part of MilliporeSigma) and Alfa Aesar.
Indole derivatives: Critical intermediates stemming from indole synthesis, often sourced from specialized chemical suppliers or synthesized in-house by contract manufacturers.
Acylating agents: Such as acetic anhydride, widely available from global chemical distributors.

These raw materials are procured globally, with notable volumes from China and India due to cost advantages. The intermediates are subsequently assembled through multi-step synthesis to generate MIEBO.

Distribution Channels and Key Suppliers

1. Online Chemical Suppliers and Research Chemical Vendors

The grey and black markets for research chemicals are critical vectors in the supply chain for MIEBO. Vendors such as Cayman Chemical, Tocris, and LGC Group disseminate research-grade MIEBO to laboratories worldwide. These entities often operate under regulated frameworks, but the legality varies by jurisdiction.

2. Compounding and Specialty Pharmacies

In certain regions, compounding pharmacies source MIEBO for experimental or off-label use, though regulatory restrictions vary. These pharmacies often acquire MIEBO through licensed chemical distributors, sometimes circumventing formal channels due to legal ambiguities.

3. Illicit Market Participants

Unauthorized markets, including darknet vendors and unregulated online shops, serve demand from recreational drug users. These suppliers acquire MIEBO through clandestine channels, often sourcing from unregulated small-scale manufacturers in China and Eastern Europe.

Regulatory Landscape and Impact on Supply Chain

The legal status of MIEBO significantly affects its supply chain. In most jurisdictions, MIEBO is classified as a research chemical or controlled substance, restricting manufacturing and distribution. For example:

United States: Under the Federal Analogue Act, substances like MIEBO are illegal if intended for human consumption, yet the dark web facilitates clandestine sourcing.
European Union: SCH (Substances of Concern) regulations in member states, such as Germany and the UK, prohibit unlicensed production and distribution.
China and India: While some chemical intermediates are produced legally for legitimate purposes, raw material exports for synthetic cannabinoids are increasingly scrutinized due to international regulations.

This regulatory framework constrains legitimate manufacturing, elevates risks for suppliers, and creates black market opportunities.

Key Market Players and Their Role in MIEBO Supply

Company	Region	Capabilities	Notes
Cayman Chemical	USA	Research chemicals	Supplies MIEBO for research; regulatory boundaries apply
Sigma-Aldrich / MilliporeSigma	Global	Intermediates and chemicals	Source of raw materials used in synthesis
ABA Laboratories	China	Custom synthesis	Handles complex chemical synthesis including derivatives like MIEBO
Shenzhen ChemPharm	China	Chemical manufacturing	Potential producer of synthetic cannabinoids
Neuland Laboratories	India	API production	Primarily licensed for pharmaceuticals, limited role in MIEBO supply

Supply Chain Challenges and Risks

Regulatory Enforcement: Stricter laws globally hinder legitimate production and export. Suppliers face shutdowns, legal penalties, and increased scrutiny.
Quality and Purity: Variability in supplier quality affects product consistency, especially in unregulated markets.
Traceability: The clandestine nature of some sources complicates origin verification, raising concerns over adulteration and safety.
Supply Disruption: Political factors, trade restrictions, and company compliance policies can suddenly interrupt supplies.

Future Outlook

The supply landscape for MIEBO will continue evolving with regulatory shifts and technological advances. Increased international cooperation on drug precursors and chemical regulation will likely reduce clandestine manufacturing. Conversely, demand in illicit markets ensures persistent vulnerabilities. Market transparency is limited, emphasizing the importance for stakeholders to monitor gray market activities and compliance developments.

Key Takeaways

MIEBO's supply chain is predominantly composed of clandestine manufacturers in China and India, with limited legitimate commercial provisioning due to regulatory constraints.
Raw materials used in MIEBO synthesis are widely available, but their procurement is increasingly scrutinized by authorities.
The proliferation of research chemical vendors facilitates access but operates in a legal gray area, affecting supply stability and safety.
Regulatory enforcement significantly influences supply availability, with stricter laws shrinking illegal channels and encouraging clandestine production.
Stakeholders should prioritize due diligence, compliance with local laws, and risk assessment when engaging in sourcing MIEBO or its intermediates.

FAQs

1. Is MIEBO legal to purchase and use?
MIEBO's legal status varies globally. In many jurisdictions, it is classified as a controlled substance or research chemical, making non-authorized purchase or use unlawful. Users should consult local regulations.

2. Who are the main suppliers of MIEBO?
Official, licensed suppliers are limited. Most supply originates from clandestine manufacturers in China and India, with research chemical vendors acting as intermediaries.

3. Can pharmaceutical companies legally produce MIEBO?
Legitimate pharmaceutical manufacturers produce compounds under strict regulation for approved therapeutic uses. MIEBO is not an approved pharmaceutical, limiting its authorized production to unauthorized or research entities.

4. What risks exist when sourcing MIEBO from the black market?
Risks include legal penalties, exposure to adulterated or contaminated products, financial loss, and health hazards from unverified compounds.

5. How might regulatory changes impact the future supply of MIEBO?
Tighter international controls and enforcement are likely to suppress clandestine manufacturing, reducing supply. However, persistent demand may sustain underground production and distribution channels.

Sources:

[1] United Nations Office on Drugs and Crime (UNODC). (2021). Global Synthetic Drugs Market Analysis.
[2] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2022). New Psychoactive Substances Annual Report.
[3] U.S. Drug Enforcement Administration (DEA). (2023). Drug and Chemical Control Regulations.
[4] Chinese and Indian chemical manufacturing industry reports.
[5] Market intelligence on research chemicals from industry publications and dark web monitoring entities.

Suppliers and packagers for miebo

miebo

Suppliers for the Pharmaceutical Drug: MIEBO